Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muzaffar Kayumov has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Sharafitdin Mirzaakhmedov

    Institute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, Uzbekistan

    7 shared publications
  • Ansor Yashinov

    Institute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, Uzbekistan

    5 shared publications
  • Nurkhodja Mukhamedov

    Institute of Bioorganic Chemistry of Uzbekistan Academy of Sciences, Tashkent, Uzbekistan

    5 shared publications
  • Abulimiti Yili

    Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, China

    4 shared publications
  • Ahmidin Wali

    Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, China

    4 shared publications
  • Akmal M. Asrorov

    Institute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, Tashkent, Uzbekistan

    3 shared publications

Latest Publications

  • Targeted Protein Degradation and Delivery Strategies in the Context of Neurological Disorders

    by Haoran Lu, Zixiao Yang, Muzaffar Kayumov, Yazhen Wang, Fanhao Tang, Xianxin Wang, Tianyue Xia, Ting Lei, Fan Tong, Huile Gao

    Neurological disorders represent a leading cause of global mortality and disability, yet treatment options remain limited due to the challenges of targeting pathogenic proteins, particularly those considered "undruggable" by conventional small molecules. Targeted protein degradation (TPD) has expanded the druggable proteome by harnessing proteasomal and lysosomal pathway to eliminate these targets, offering the advantages of lower toxicity and reduced resistance compared to traditional modulation. This review systematically delineates TPD mechanisms according to their degradation pathways, including proteasomal, endosomal-lysosomal, and autophagy-lysosomal systems, and highlights their unique applications in brain diseases. However, the translation of TPD to neurological disease is limited by physicochemical liabilities, cell-type dependence, risks associated with whole-protein ablation, the blood-brain barrier (BBB) and poor brain bioavailability. To address these translational barriers, we emphasize the integration of TPD with drug delivery systems (DDS) as a pivotal strategy. By optimizing pharmacokinetics, stability, and BBB penetration, nano-DDS significantly enhances brain targeting and therapeutic precision. Finally, we evaluate recent progress in nano-TPD systems and offer critical insights into their future trajectory in treating complex brain disorders.


  • 3CLpro of SARS-CoV-2 as a new target for bufadienolides: in silico and in vitro study

    by Muzaffar Kayumov, Jamoliddin Razzokov, Mukhriddin Makhkamov, Murodjon Radjabov, Nurkhodja Mukhamedov, Makhmudjon Khakimov, Akmal M. Asrorov, Okhunjon Khasanov, Ansor Yashinov, Mugrajitdin Tashmukhamedov, et al.

    The rapid spread of SARS-CoV-2 and its widespread public health implications have highlighted the urgent need for effective antiviral therapies. A promising strategy is to investigate natural compounds that may inhibit the key viral targets. In this work, we demonstrated the anti-SARS-CoV-2 activity of six bufadienolides, including bufalin (A), arenobufagin (B), gamabufotalin (C), telocinobufagin (D), marinobufagin (E), and bufarenogin (F) from the venom of the Central Asian green toad, Bufo viridis. Molecular docking assays revealed that all A-F bufadienolides bind to key residues (Thr26, His41, Met49, Met161, and Gln189) in the catalytic pocket of 3-chymotrypsin-like cysteine protease (3CLpro), an essential enzyme for viral replication and polyprotein processing. The stability of the protein-ligand complexes was then tested using molecular dynamics (MD) simulations, while the binding free energies were estimated using the umbrella sampling (US) technique. Compounds A (-49.8 ± 1.0 kJ/mol), C (-45.9 ± 1.8 kJ/mol), E (-45.6 ± 1.1 kJ/mol), and F (-45.8 ± 1.9 kJ/mol) had significantly higher binding affinities than compounds B (-14.6 ± 1.1 kJ/mol) and D (-10.3 ± 1.9 kJ/mol). In vitro enzymatic assays also confirmed these results, demonstrating that A and C exhibited potent inhibitory activity against 3CLpro with IC50 values of 1.37 µM and 2 µM, respectively, compared to the other bufadienolides; however, they were less active than the positive control GC376 (IC50 = 0.27 µM). The experimental results are consistent with the computational observations. In silico ADME profiling also revealed good pharmacokinetic properties, indicating that bufadienolides A-F are lead compounds for further antiviral drug development. Taken together, our results support the hypothesis that bufadienolides are SARS-CoV-2 3CLpro inhibitors and elucidate their mechanism of action, thereby laying the foundation for potential therapeutic advances against COVID-19.


  • Open Access

    Computational and in vitro evaluation of sumac-derived ©Rutan compounds towards Sars-CoV-2 Mpro inhibition

    by Muzaffar Kayumov, Parthiban Marimuthu, Jamoliddin Razzokov, Nurkhodja Mukhamedov, Akmal Asrorov, Nodir S. Berdiev, Jamolitdin F. Ziyavitdinov, Ansor Yashinov, Yuliya Oshchepkova, Shavkat Salikhov, et al.

    The emergence of the SARS-CoV-2 virus caused the COVID-19 outbreak leading to a global pandemic. Natural substances started being screened for their antiviral activity by computational and in-vitro techniques. Here, we evaluated the anti-SARS-CoV-2 main protease (Mpro) efficacy of ©Rutan, which contains five polyphenols (R5, R6, R7, R7’, and R8) extracted from sumac Rhus coriaria L. We obtained three fractions after large-scale purification: fraction 1 held R5, fraction 2 consisted of R6, R7 and R7’, and fraction 3 held R8. In vitro results showed their anti-Mpro potential: IC50 values of R5 and R8 made 42.52 µM and 5.48 µM, respectively. Further, we studied Mpro-polyphenol interactions by in silico analysis to understand mechanistic extrapolation of Rutan binding nature with Mpro. We extensively incorporated a series of in silico techniques. Initially, for the docking protocol validation, redocking of the co-crystal ligand GC-376* to the binding pocket of Mpro was carried out. The representative docked complexes were subjected to long-range 500 ns molecular dynamics simulations. The binding free energy (BFE in kcal/mol) of components were calculated as follows: R8 (−104.636) > R6 (−93.754) > R7’ (−92.113) > R5 (−81.115) > R7 (−67.243). In silico results of R5 and R8 correspond with their in vitro outcomes. Furthermore, the per-residue decomposition analysis showed C145, E166, and Q189 residues as the hotspot residues for components contributing to maximum BFE energies. All five components effectively interact with the catalytic pocket of Mpro and form stable complexes that allow the estimation of their inhibitory activity. Assay kit analyses revealed that Rutan and its components have effective anti-SARS-CoV-2 Mpro inhibitory activity.


  • A new polymorphic form of 3b,11a,14-trihydroxy-5b,14b-bufa-20,22-dienolide (telocinobufagin) and its p300 and NNMT inhibitory activity

    by Muzaffar Kayumov, Nurkhodja Mukhamedov, Jamshid Ashurov, Alisher Eshimbetov, Akmal M. Asrorov, Ansor Yashinov, Mugrajitdin Tashmukhamedov, Ahmidin Wali, Abulimiti Yili, Bakhtiyar Ibragimov, et al.


  • Food Protein‐Derived Zinc‐Binding Peptides: Isolation, Purification, and Biological Aspects

    by Nurkhodja Mukhamedov, Akmal M. Asrorov, Muzaffar Kayumov, Ahmidin Wali, Haji Akber Aisa, Sharafitdin Mirzaakhmedov, Abulimiti Yili

    Zinc is the second most valuable microelement after iron, according to its abundance in the human body. Supplementation of this metal is not straightforward because of several factors like phytates and interference of other minerals during gastrointestinal digestion. For the last several years, intensive research has been developing new forms of zinc supplements based on zinc‐binding peptides from food products. Except for the advantages of supplementation, zinc‐peptide complexes are expected to be drug candidates against various diseases. Zinc supplementation can be improved by protein hydrolysates and peptides due to their zinc‐binding ability. They enhance zinc supplementation and contribute to preventing conditions leading to zinc deficiency that cause various diseases. Research on food‐derived zinc‐binding peptides is progressing in two directions: the isolation and identification of individual peptides (1) and the preparation of zinc complexes of protein hydrolysates (2). Both approaches are primarily aimed at developing effective mineral supplements, although some work on the second approach is also related to nutrition and therapy. Because zinc–protein hydrolysate complexes are nonstandardized mixtures of peptides, their biological activity mechanisms can be difficult to study. Therefore, it is important to focus more research on the biological activity of individual zinc‐binding complexes and their zinc complexes. This work reviewed recent advances in isolating and identifying zinc‐binding peptides from food sources, preparing protein hydrolysate–zinc complexes, and their biological activities. The established sequences of zinc‐binding peptides have been compiled into a table to review their amino‐acid composition and sequence. We also highlighted approaches for isolating and determining the zinc‐binding capacity of peptides in this class. The structural features of peptides affecting their zinc‐binding property were discussed in one section.


  • Open Access

    Albumin is a reliable drug-delivering molecule: Highlighting points in cancer therapy

    by Akmal M. Asrorov, Nurkhodja Mukhamedov, Muzaffar Kayumov, Ansor Sh. Yashinov, Ahmidin Wali, Abulimiti Yili, Sharafitdin Ya. Mirzaakhmedov, Yongzhuo Huang


  • Synthesis and Characterisation of Chickpea Peptides-Zinc Chelates Having ACE2 Inhibitory Activity

    by Nurkhodja Mukhamedov, Akmal Asrorov, Ansor Yashinov, Muzaffar Kayumov, Ahmidin Wali, Sharafitdin Mirzaakhmedov, Haji Akber Aisa, Abulimiti Yili

    Tryptic hydrolysates of protein fractions obtained by the Osborne method from chickpea (Cicer arietinum L.) seeds interacted with zinc ions and the results of chelation were monitored by the Energy Dispersive X-Ray (EDX) technique. The glutelin hydrolysate (GluHyd) reacted with zinc ions and depicted a relatively higher zinc content. For this reason, the zinc complex of the glutelin hydrolysate (GluHyd-Zn) was studied deeper, and 11 peptides were identified in its more zinc-containing second fraction obtained after gel filtration. The peptide HKERVQLHIIPTAVGK showed a relatively higher chelating capacity (57.86 ± 2.14%). According to the result of the ICP-OS analysis, 1 mg peptide could chelate 381.61 ± 133.39 µg zinc, and the molar ratio of peptide-zinc was about 1:4. Spectral methods proved that side chain and C-termini carboxyl groups of the peptide mostly were involved in chelation and N atoms of amino side chains, imidazole group of histidine, and N-termini at some extents were occupied by the metal ions. Modeling of zinc-peptide interaction was done using Molecular Operating Environment (MOE) software. The results of the docking correlate with the experimental data. ACE2 inhibitory effect of HKERVQLHIIPTAVGK-Zn complex (IC50 = 1.5 mg/mL) was better than that of HKERVQLHIIPTAVGK (IC50 = 2.2 mg/mL).


  • Toad venom bufadienolides and bufotoxins: An updated review

    by Akmal M. Asrorov, Muzaffar Kayumov, Nurkhodja Mukhamedov, Ansor Yashinov, Ziyoda Mirakhmetova, Yongzhuo Huang, Abulimiti Yili, Haji Akber Aisa, Mugrajitdin Tashmukhamedov, Shavkat Salikhov, et al.

    Bufadienolides, naturally found in toad venoms having steroid‐like structures, reveal antiproliferative effects at low doses. However, their application as anticancer drugs is strongly prevented by their Na+/K+‐ATPase binding activities. Although several kinds of research were dedicated to moderating their Na+/K+‐ATPase binding activity, still deeper fundamental knowledge is required to bring these findings into medical practice. In this work, we reviewed data related to anticancer activity of bufadienolides such as bufalin, arenobufagin, bufotalin, gamabufotalin, cinobufotalin, and cinobufagin and their derivatives. Bufotoxins, derivatives of bufadienolides containing polar molecules mainly belonging to argininyl residues, are reviewed as well. The established structures of bufotoxins have been compiled into a one‐page figure to review their structures. We also highlighted advances in the structure‐modification of the structure of compounds in this class. Drug delivery approaches to target these compounds to tumor cells were discussed in one section. The issues related to extraction, identification, and quantification are separated into another section.


  • Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone

    by Muzaffar Kayumov, Li Jia, Azizbek Pardaev, Shan-Shan Song, Sharafitdin Mirzaakhmedov, Chunyong Ding, Yong-Jun Cheng, Ruihan (Isabella) Zhang, Xubin Bao, Ze-Hong Miao, et al.


  • Synthesis of Arylstannanes via Palladium‐Catalyzed Decarbonylative Coupling of Aroyl Fluorides

    by Muzaffar Kayumov, Jian‐Nan Zhao, Sharafitdin Mirzaakhmedov, Dong‐Yu Wang, Ao Zhang

    Aryl stannanes are valuable precursors in organic transformations, but their synthetic methods are limited. Here we present a Pd‐catalyzed decarbonylative stannylation of acid fluorides in the absence of exogenous base. Various aryl stannanes were efficiently prepared from bench‐stable transition metal catalyst and ligand with broad functional group compatibility and substrate scope including natural products and pharmaceuticals. This protocol was also successfully used to a late‐stage diversification of an existing uricosuric drug probenecid. magnified image